In the preceding three months, 11 analysts have released ratings for Celldex Therapeutics CLDX, presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 5 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 1 | 1 | 0 | 0 |
| 3M Ago | 0 | 4 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Celldex Therapeutics, presenting an average target of $68.55, a high estimate of $80.00, and a low estimate of $45.00. This current average has decreased by 3.45% from the previous average price target of $71.00.
Analyzing Analyst Ratings: A Detailed Breakdown
A comprehensive examination of how financial experts perceive Celldex Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $80.00 | $80.00 |
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $80.00 | $80.00 |
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $80.00 | $80.00 |
| David Lebowitz | Citigroup | Announces | Buy | $70.00 | - |
| Richard Law | Goldman Sachs | Announces | Neutral | $45.00 | - |
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $80.00 | $80.00 |
| Andy Chen | Wolfe Research | Maintains | Outperform | $51.00 | $51.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $67.00 | $67.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $67.00 | $67.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $67.00 | $67.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $67.00 | $67.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Celldex Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Celldex Therapeutics compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Celldex Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.
To gain a panoramic view of Celldex Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Celldex Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Get to Know Celldex Therapeutics Better
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
Celldex Therapeutics: Delving into Financials
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Celldex Therapeutics showcased positive performance, achieving a revenue growth rate of 110.35% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Celldex Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1319.99% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Celldex Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -5.27%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Celldex Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of -5.05%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Celldex Therapeutics's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
What Are Analyst Ratings?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
